Picard Medical Reports 207% Revenue Growth but Incurred $6.7 Million Net Loss in Q2 2025

Picard Medical, Inc. reported its financial results for the second quarter of 2025, revealing a total revenue of $2.1 million, a significant increase of 207% compared to $694,000 in the same period last year. For the six months ending June 30, 2025, revenues reached $2.7 million, up 3% from $2.7 million in the prior year. The growth in revenue was primarily driven by increased sales of the SynCardia total artificial heart in the U.S. market, which saw a rise of $1.4 million. However, the company also faced rising costs, with total cost of revenues increasing by 110% to $2.3 million for the quarter, leading to a gross loss of $127,000.

The company’s operating expenses remained relatively stable, totaling $3.4 million for the quarter, a slight decrease from $3.4 million in the previous year. Research and development costs decreased by 21% to $743,000, while selling, general, and administrative expenses increased by 6% to $2.7 million. Despite these efforts, Picard Medical reported a net loss of $6.7 million for the quarter, compared to a loss of $4.1 million in the same quarter of 2024. The increase in net loss was attributed to a substantial rise in interest expenses and derivative losses related to convertible notes.

In terms of operational developments, Picard Medical has been focusing on expanding its market presence and product offerings. The company has successfully implanted over 2,100 SynCardia total artificial hearts across 27 countries, including the U.S., Canada, and several European nations. The company is also actively pursuing patent protections for its next-generation total artificial heart technology, which is expected to enhance its competitive position in the cardiovascular market.

The company’s financial position showed a slight improvement, with cash and cash equivalents increasing to $410,000 as of June 30, 2025, compared to $96,000 at the end of 2024. However, total liabilities rose significantly to $45.9 million, up from $35.8 million, primarily due to increased accounts payable and loans from related parties. The company continues to face challenges in achieving profitability, with management indicating that additional financing will be necessary to support ongoing operations and growth initiatives.

Looking ahead, Picard Medical remains focused on scaling its operations and enhancing its product offerings. The company has indicated that it will continue to seek additional funding through equity and debt financing to support its growth strategy. However, there is substantial doubt regarding its ability to continue as a going concern, as it has incurred operating losses since inception and will need to generate positive cash flows to sustain its operations. The company’s future performance will depend on its ability to increase sales and manage its costs effectively while navigating the complexities of the medical device market.